{"id":"mitomycin-c-mmc","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (thrombocytopenia, leukopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hemolytic uremic syndrome"},{"rate":null,"effect":"Pulmonary toxicity"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":{"chemblId":"CHEMBL105","moleculeType":"Small molecule","molecularWeight":"334.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MMC is a naturally derived antibiotic that acts as a bifunctional alkylating agent. After metabolic activation, it covalently binds to DNA and forms inter- and intra-strand cross-links, blocking DNA replication and transcription. This leads to cell cycle arrest and apoptosis, making it effective against rapidly dividing cancer cells.","oneSentence":"Mitomycin C is an alkylating agent that cross-links DNA strands, preventing cell division and triggering cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:33.269Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Pancreatic cancer"},{"name":"Colorectal cancer"},{"name":"Bladder cancer (intravesical)"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT07496957","phase":"NA","title":"Preserflo MicroShunt Versus Trabeculectomy","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2026-03-01","conditions":"GLAUCOMA 1, OPEN ANGLE, D (Disorder)","enrollment":100},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07487168","phase":"PHASE1","title":"Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":"Peritoneal Carcinomatosis","enrollment":24},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT07303257","phase":"","title":"Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-23","conditions":"Glaucoma Eye, Open-angle Glaucoma, Closed-Angle Glaucoma","enrollment":132},{"nctId":"NCT07475286","phase":"PHASE2","title":"Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis","status":"NOT_YET_RECRUITING","sponsor":"Mohammad Haroon Asif Choudry","startDate":"2026-04-30","conditions":"Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis","enrollment":22},{"nctId":"NCT06319820","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-18","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":641},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220},{"nctId":"NCT05672108","phase":"PHASE2","title":"Phase II Trial of Lung Chemoemobolization","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-12","conditions":"Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm","enrollment":30},{"nctId":"NCT03348969","phase":"PHASE4","title":"Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC","status":"COMPLETED","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2017-11-01","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT07282834","phase":"PHASE2","title":"Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)","status":"RECRUITING","sponsor":"Patrick Wagner, MD, FACS","startDate":"2026-01-05","conditions":"Peritoneal (Metastatic) Cancer, Peritoneal Carcinomatosis, Abdominal Cancer","enrollment":200},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT07425743","phase":"NA","title":"Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2022-11-07","conditions":"Open Angle Glaucoma (OAG)","enrollment":26},{"nctId":"NCT07425054","phase":"PHASE2","title":"HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jennifer Dorth","startDate":"2026-03","conditions":"Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus","enrollment":33},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT06513065","phase":"PHASE3","title":"Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2024-12-04","conditions":"Pseudomyxoma Peritonei","enrollment":176},{"nctId":"NCT01858025","phase":"EARLY_PHASE1","title":"Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-07","conditions":"Carcinoma of the Anal Canal","enrollment":25},{"nctId":"NCT05316181","phase":"PHASE3","title":"CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2022-04-07","conditions":"Epithelial Ovarian Cancer, Platinum Resistant, Recurrent Ovarian","enrollment":140},{"nctId":"NCT01815359","phase":"PHASE2","title":"ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-03","conditions":"Appendix Cancer, Colorectal Cancer","enrollment":292},{"nctId":"NCT05838391","phase":"NA","title":"Adaptive Radiation in Anal Cancer","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-18","conditions":"Anal Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT03386500","phase":"PHASE1, PHASE2","title":"Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2017-11-28","conditions":"Anal Cancer, Squamous Cell Carcinoma, Radiation Exposure","enrollment":24},{"nctId":"NCT07358650","phase":"NA","title":"Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma","status":"RECRUITING","sponsor":"Hexiris Inc","startDate":"2026-01-15","conditions":"Primary Open Angle Glaucoma","enrollment":25},{"nctId":"NCT07359547","phase":"NA","title":"Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-01","conditions":"GLAUCOMA 1, OPEN ANGLE, D (Disorder)","enrollment":166},{"nctId":"NCT07350200","phase":"NA","title":"XEN Glaucoma Implant for the Management of Operated Uncontrolled Glaucoma: Results and Complications During a Long-Term Follow-Up","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2014-12-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT06774131","phase":"PHASE3","title":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","status":"RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2025-08-06","conditions":"Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma","enrollment":70},{"nctId":"NCT07349043","phase":"PHASE1","title":"A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01","conditions":"Peritoneal Metastasis, CRC (Colorectal Cancer)","enrollment":42},{"nctId":"NCT06331299","phase":"PHASE3","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2024-08-29","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":99},{"nctId":"NCT07313579","phase":"","title":"Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","status":"RECRUITING","sponsor":"Ukrainian Society of Clinical Oncology","startDate":"2025-12-01","conditions":"Gastric Cancer (GC), HIPEC, Peritoneal Metastases From Gastric Cancer","enrollment":200},{"nctId":"NCT06478862","phase":"PHASE2","title":"Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy","status":"TERMINATED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2024-06-13","conditions":"Cancer of Ovary, Pancreatic Ductal Adenocarcinoma","enrollment":19},{"nctId":"NCT04779554","phase":"PHASE2","title":"Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC","status":"RECRUITING","sponsor":"Prakash Pandalai","startDate":"2021-06-04","conditions":"Peritoneal Carcinomatosis","enrollment":100},{"nctId":"NCT01226550","phase":"PHASE1, PHASE2","title":"Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2007-06","conditions":"Peritoneal Carcinosis (PC)","enrollment":18},{"nctId":"NCT05902533","phase":"PHASE2, PHASE3","title":"REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2023-08-14","conditions":"Anal Cancer","enrollment":33},{"nctId":"NCT04858009","phase":"PHASE2","title":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-02-15","conditions":"Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":40},{"nctId":"NCT07043543","phase":"NA","title":"Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)","status":"NOT_YET_RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2026-01-15","conditions":"Bladder Cancer","enrollment":120},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT07231809","phase":"NA","title":"Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"AC.TA. S.r.l.","startDate":"2026-01-15","conditions":"Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder","enrollment":50},{"nctId":"NCT02369458","phase":"PHASE2","title":"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-04-14","conditions":"Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck","enrollment":48},{"nctId":"NCT06822010","phase":"PHASE2","title":"SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2026-06-01","conditions":"Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer","enrollment":28},{"nctId":"NCT04216290","phase":"PHASE2","title":"A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8","enrollment":95},{"nctId":"NCT00183885","phase":"PHASE2","title":"A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2004-10-18","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":76},{"nctId":"NCT04107077","phase":"PHASE2","title":"Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-09-09","conditions":"Gastric Cancer, Peritoneal Carcinomatosis","enrollment":21},{"nctId":"NCT06781879","phase":"PHASE4","title":"Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Jakob Kristian Jakobsen","startDate":"2025-06-01","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":272},{"nctId":"NCT05040815","phase":"PHASE2","title":"Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2023-05-11","conditions":"Anal Canal Cancer","enrollment":45},{"nctId":"NCT07152132","phase":"NA","title":"SCTSC Versus Trabeculectomy in Medically Uncontrolled Open-Angle Glaucoma in Pseudophakic Patients","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-07-20","conditions":"Glaucoma, Open Angle","enrollment":50},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT02701088","phase":"PHASE2","title":"Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Francois Baclesse","startDate":"2015-12","conditions":"Locally Advanced Anal Canal Cancer","enrollment":71},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT06388720","phase":"PHASE2","title":"The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-11-19","conditions":"Bladder Cancer","enrollment":82},{"nctId":"NCT07173023","phase":"NA","title":"A Comparative Study of Endoscopic Choanal Canalization and Mitomycin C Application vs Endoscopic Crossover Flap Technique","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09","conditions":"Choanal Atresia","enrollment":30},{"nctId":"NCT06783569","phase":"PHASE1","title":"A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"JiaRay Group","startDate":"2024-12-31","conditions":"Solid Tumors, Gastric Cancer, Esophagogastric Juction Cancer","enrollment":94},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT03648814","phase":"NA","title":"Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT","status":"RECRUITING","sponsor":"Prince of Songkla University","startDate":"2018-08-01","conditions":"Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression","enrollment":40},{"nctId":"NCT02363400","phase":"PHASE3","title":"A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2014-12-14","conditions":"Nasopharyngeal Carcinoma","enrollment":10},{"nctId":"NCT04046133","phase":"PHASE1","title":"Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff University","startDate":"2020-10-19","conditions":"Anal Cancer Stage III A, Anal Cancer Stage III B","enrollment":52},{"nctId":"NCT02106572","phase":"PHASE3","title":"Therapeutic Instillation of Mistletoe","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abnoba Gmbh","startDate":"2015-04","conditions":"Superficial Bladder Cancer","enrollment":548},{"nctId":"NCT07034651","phase":"NA","title":"Electron Microscopic Examination of Iris Tissue in Buphthalmos","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-06-01","conditions":"Iris Diseases","enrollment":20},{"nctId":"NCT06993311","phase":"","title":"Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma","status":"COMPLETED","sponsor":"Xerencia de Xestión Integrada de Ferrol","startDate":"2018-01-01","conditions":"Pseudoexfoliation Syndrome, Pseudoexfoliation Glaucoma in Both Eyes, Open Angle Glaucoma","enrollment":350},{"nctId":"NCT06983704","phase":"EARLY_PHASE1","title":"Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-02-09","conditions":"Pediatric Glaucoma","enrollment":50},{"nctId":"NCT04200417","phase":"PHASE1","title":"Chemoembolization for Lung Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-13","conditions":"Lung Metastases, Endobronchial Metastases, Pleural Metastases","enrollment":10},{"nctId":"NCT06944132","phase":"NA","title":"CsA vs MMC for Preventing Pterygium Recurrence","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-04-01","conditions":"Pterygium, Pterygium of the Conjunctiva and Cornea","enrollment":40},{"nctId":"NCT05365672","phase":"PHASE2","title":"Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation","status":"RECRUITING","sponsor":"TolerogenixX GmbH","startDate":"2022-05-04","conditions":"Kidney Transplantation","enrollment":126},{"nctId":"NCT06735287","phase":"NA","title":"A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":"Bladder Cancer, NMIBC","enrollment":60},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":"Bladder Cancer, Non-muscle Invasive","enrollment":34},{"nctId":"NCT05494411","phase":"","title":"Named Patient Program for Mitomycin for Pyelocalyceal Solution","status":"AVAILABLE","sponsor":"UroGen Pharma Ltd.","startDate":"","conditions":"Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Ureter","enrollment":""},{"nctId":"NCT05874921","phase":"","title":"uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto","status":"RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2023-11-17","conditions":"Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter","enrollment":400},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT05430035","phase":"EARLY_PHASE1","title":"Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2022-06-23","conditions":"Gallbladder Adenocarcinoma","enrollment":10},{"nctId":"NCT06696794","phase":"PHASE3","title":"Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients","status":"RECRUITING","sponsor":"Shaogang Wang","startDate":"2025-02-17","conditions":"Non-Muscle-Invasive Bladder Cancer (NMIBC)","enrollment":180},{"nctId":"NCT03092518","phase":"PHASE2","title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-05","conditions":"Gastric Adenocarcinoma, Esophagogastric Junction, Gastric Cancer","enrollment":27},{"nctId":"NCT03422432","phase":"NA","title":"Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2017-09-28","conditions":"Colorectal Cancer, Peritoneal Metastases","enrollment":17},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06768346","phase":"NA","title":"Hyperthermic Intra-Vesical Chemotherapy","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2014-05-08","conditions":"Bladder Cancer","enrollment":259},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT02710734","phase":"PHASE2","title":"Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2016-02-24","conditions":"Urothelial Carcinoma of the Bladder","enrollment":78},{"nctId":"NCT04719988","phase":"PHASE2","title":"Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-01-04","conditions":"Squamous Cell Carcinoma of the Anus Stage III","enrollment":55},{"nctId":"NCT06734663","phase":"NA","title":"Clinical Outcomes of Sutured Versus Sutureless Conjunctival Autograft in Primary Pterygium Excision","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-12-15","conditions":"Pterygium of Conjunctiva and Cornea, Pterygium of Both Eyes, Pterygium","enrollment":70},{"nctId":"NCT01905150","phase":"PHASE2","title":"Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer","status":"COMPLETED","sponsor":"Bruckner Oncology","startDate":"2014-08-13","conditions":"Pancreatic Cancer","enrollment":34},{"nctId":"NCT04241185","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-19","conditions":"Urinary Bladder Neoplasms","enrollment":520},{"nctId":"NCT06680245","phase":"PHASE3","title":"Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2024-12-01","conditions":"Glaucoma","enrollment":144},{"nctId":"NCT03658304","phase":"PHASE2","title":"Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma","status":"COMPLETED","sponsor":"University of Florida","startDate":"2018-12-05","conditions":"Urothelial Carcinoma","enrollment":29},{"nctId":"NCT05243550","phase":"PHASE3","title":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2022-03-01","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":240},{"nctId":"NCT02040142","phase":"PHASE2","title":"HIPEC for Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2011-11","conditions":"Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer","enrollment":51},{"nctId":"NCT05250648","phase":"PHASE4","title":"Clinical Trial on HIPEC with Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)","status":"RECRUITING","sponsor":"Hospital Universitario de Fuenlabrada","startDate":"2022-03-02","conditions":"Peritoneal Carcinomatosis, Colon Cancer","enrollment":216},{"nctId":"NCT06626802","phase":"NA","title":"Steroid Versus Mitomycin-C Use in Pediatric Benign Recurrent Esophageal Stricture","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2023-07-01","conditions":"Esophageal Stricture","enrollment":24},{"nctId":"NCT00981656","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-11","conditions":"Bladder Cancer","enrollment":37},{"nctId":"NCT03018418","phase":"PHASE2","title":"Proton Therapy in Reducing Toxicity in Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jordan Kharofa","startDate":"2017-01-04","conditions":"Anus Neoplasms","enrollment":14},{"nctId":"NCT02891447","phase":"PHASE2","title":"Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-09-01","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":24},{"nctId":"NCT04230759","phase":"PHASE2","title":"Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group","status":"ACTIVE_NOT_RECRUITING","sponsor":"Goethe University","startDate":"2020-01-07","conditions":"Anal Cancer, Anal Carcinoma, Anal Cancer Stage III","enrollment":180},{"nctId":"NCT05136898","phase":"PHASE3","title":"Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2021-11-30","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":8},{"nctId":"NCT06393855","phase":"NA","title":"Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain","status":"RECRUITING","sponsor":"Dongyang People's Hospital","startDate":"2024-06-18","conditions":"Myopia","enrollment":36},{"nctId":"NCT01581840","phase":"PHASE1, PHASE2","title":"Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-01","conditions":"Epidermoid Carcinoma, Anus","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4479,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Mitomycin C (MMC)","genericName":"Mitomycin C (MMC)","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mitomycin C is an alkylating agent that cross-links DNA strands, preventing cell division and triggering cancer cell death. Used for Gastric cancer, Pancreatic cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}